Clinical Trial: Study to Compare Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma (NIMBUS)
Sponsor and Collaborators
Celgene Corporation
Contact
Contact: Associate Director, Clinical Trial Disclosure
1-888-260-1599
clinicaltrialdisclosure@celgene.com
Principal Investigator
Study Director: Mohamed Zaki, MD, PhD Celgene Corporation
ClinicalTrials.gov Identifier
NCT01311687